Environment, Mitochondria, and Parkinson's Disease

@article{Sherer2002EnvironmentMA,
  title={Environment, Mitochondria, and Parkinson's Disease},
  author={T. Sherer and R. Betarbet and J. T. Greenamyre},
  journal={The Neuroscientist},
  year={2002},
  volume={8},
  pages={192 - 197}
}
Parkinson's disease (PD) is a common and disabling neurodegenerative disease marked by progressive motor dysfunction, which results from selective degeneration of the nigrostriatal pathway. Epidemiological studies indicate that exposure to pesticides, rural living, farming, and drinking well water are associated with an increased risk of developing PD. Rare cases of PD are caused by mutations in nuclear genes, and there is increasing evidence for susceptibility genes that alter disease risk… Expand
Mitochondrial Dysfunction in Parkinson's Disease
TLDR
A considerable body of evidence linking mitochondrial dysfunction with neuronal cell death in the substantia nigra pars compacta of PD patients is illustrated and the important need for further research in this area is highlighted. Expand
Mitochondrial Dysfunction and Oxidative Stress in Parkinson’s Disease
  • I. Onyango
  • Biology, Medicine
  • Neurochemical Research
  • 2007
TLDR
Molecular studies in both toxin based models and genetic based models of Parkinson’s disease suggest a major etiologic role for mitochondrial dysfunction in the pathogenesis of PD. Expand
Mitochondrial Proteins in the Development of Parkinson's Disease.
TLDR
The mitochondrial dysfunctions in toxin-induced models of PD are described, highlighting the importance of environmental factors in the onset of this pathology and clarifying the important role played by proteomics. Expand
Molecular pathophysiology of Parkinson's disease.
TLDR
Increasing evidence indicates that deficits in mitochondrial function, oxidative and nitrosative stress, the accumulation of aberrant or misfolded proteins, and ubiquitin-proteasome system dysfunction may represent the principal molecular pathways or events that commonly underlie the pathogenesis of sporadic and familial forms of PD. Expand
Molecular Pathways of Neurodegeneration in Parkinson's Disease
TLDR
Strategies aimed at restoring complex I activity, reducing oxidative stress and α-synuclein aggregation, and enhancing protein degradation may hold particular promise as powerful neuroprotective agents in the treatment of PD. Expand
New insights on Parkinson’s disease genes: the link between mitochondria impairment and neuroinflammation
TLDR
The link between PD-related genes, which are involved in mitochondrial function, and deleterious neuroinflammation is described, which was demonstrated mostly in neuronal cells. Expand
Mitochondrial therapy for Parkinson’s disease: Neuroprotective pharmaconutrition may be disease-modifying
  • R. Kones
  • Medicine
  • Clinical pharmacology : advances and applications
  • 2010
TLDR
Coenzyme Q10 and creatine, two agents involved in energy production, may be disease-modifying, and able to produce sufficient beneficial pathophysiologic changes in preclinical studies to warrant large studies now in progress. Expand
Analysis of copy number variation and disease mechanisms underlying Parkinson’s disease
TLDR
A cellular model of PD was created by decreasing the expression of PINK1 in SH-SY5Y neuroblastoma cells and the protective effects of curcumin was tested on this model in the presence and absence of a known stressor, paraquat. Expand
Inflammation, Infectious Triggers, and Parkinson's Disease
TLDR
The different aspects of inflammation and immune system in Parkinson's disease are reported, with particular interest in the possible role played by immune dysfunctions in PD, with focus on autoimmunity and processes involving infectious agents as a trigger and alpha-synuclein protein (α-syn). Expand
Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition.
  • R. Kones
  • Medicine
  • Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
  • 2010
TLDR
Two agents of current interest, coenzyme Q10 and creatine, may be disease modifying, and large studies are in progress, and related mechanisms of other substances, including omega-3 fatty acids and vitamin D, are included in this review. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 48 REFERENCES
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
TLDR
It is reported that chronic, systemic inhibition of complex I by the lipophilic pesticide, rotenone, causes highly selective nigrostriatal dopaminergic degeneration that is associated behaviorally with hypokinesia and rigidity. Expand
Response: Parkinson's disease, pesticides and mitochondrial dysfunction
TLDR
The results clearly suggest that a modest systemic defect in a ubiquitous mitochondrial enzyme might be central to PD pathogenesis, and typical complex I assays are relatively insensitive to all but gross defects. Expand
Human complex I defects in neurodegenerative diseases.
  • A. Schapira
  • Biology, Medicine
  • Biochimica et biophysica acta
  • 1998
TLDR
Recent work with rho degrees cybrids indicates that, in a subgroup of patients at least, the complex I deficiency is determined by mtDNA, in contrast to dystonia where a nuclear gene defect or toxic influence appears a more likely cause. Expand
Origin and functional consequences of the complex I defect in Parkinson's disease
TLDR
The complex I defect in PD appears to be genetic, arising from mitochondrial DNA, and may play an important role in the neurodegeneration of PD by fostering reactive oxygen species production and conferring increased neuronal susceptibility to mitochondrial toxins. Expand
Mitochondrial Complex I Deficiency in Parkinson's Disease
TLDR
Results indicated a specific defect of Complex I activity in the substantia nigra of patients with Parkinson's disease, which adds further support to the proposition that Parkinson’s disease may be due to an environmental toxin with action(s) similar to those of MPTP. Expand
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
TLDR
A mutation was identified in the α-synuclein gene, which codes for a presynaptic protein thought to be involved in neuronal plasticity, in the Italian kindred and in three unrelated families of Greek origin with autosomal dominant inheritance for the PD phenotype. Expand
Abnormalities of the electron transport chain in idiopathic parkinson's disease
TLDR
It is hypothesized that the complex I abnormality may have an etiological role in the pathogenesis of Parkinson's disease and that this defect may be derived via the mitochondrial genome. Expand
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.
TLDR
A mutation was identified in the alpha-synuclein gene, which codes for a presynaptic protein thought to be involved in neuronal plasticity, in the Italian kindred and in three unrelated families of Greek origin with autosomal dominant inheritance for the PD phenotype. Expand
Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease
TLDR
Results support the proposition that an mtDNA abnormality may underlie the mitochondrial defect in at least a proportion of PD patients and use of a mtDNA‐less (μo) cell line to determine if the complex I deficiency follows the genomic transplantation of platelet mtDNA. Expand
A Generalised Increase in Protein Carbonyls in the Brain in Parkinson's but Not Incidental Lewy Body Disease
TLDR
The data show that either oxidative protein damage occurs widely but late in PD brain, and/or that l‐DOPA treatment contributes to protein oxidation. Expand
...
1
2
3
4
5
...